PeptiDream grants Shionogi non-exclusive license to its PDPS peptide discovery technology

Shionogi & Co. Ltd. (Tokyo:4507) gained a non-exclusive license from PeptiDream Inc. (Tokyo:4587) to use its Peptide Discovery Platform System (PDPS) technology to discover macrocyclic and constrained peptides for any target or indication. PeptiDream said the license excludes peptide-drug conjugates.

PeptiDream will receive an upfront payment, as well as additional technology access payments over five years, and is eligible for development milestones and royalties. The company said financial details are undisclosed. Shionogi did not respond to inquiries...